1 Min Read
July 20 (Reuters) - Johnson & Johnson :
* Health Canada approves Imbruvica (ibrutinib) for first-line treatment of chronic lymphocytic leukemia Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.